Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric-Inspired Chemotherapy + Venetoclax + Immunotherapy in Adult Ph-Negative ALL
NCT07495631Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Open-label trial of venetoclax, blinatumomab and inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Event-Free Survival up to 5 years and Minimal Residual Disease-negative Complete Remission rate by flow cytometry up to 6 weeks. Started Apr 2026; status: recruiting.
02
Drugs
venetoclaxblinatumomabinotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07495631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495631.